Oxcarbazepine in the treatment of affective and schizoaffective disorders;Oxcarbazepin in der behandlung affektiver und schizoaffektiver erkrankungen

Fortschritte der Neurologie Psychiatrie

Volumn 71, Issue 5, 2003, Pages 255-264

  Dietrich, D E ^a   Kropp, S ^a   Emrich, H M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; ETHINYLESTRADIOL; FELODIPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OXCARBAZEPINE; PSYCHOTROPIC AGENT; VALPROIC ACID; VERAPAMIL;

ARTICLE; DERMATITIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPONATREMIA; LEUKOPENIA; MANIA; MOOD DISORDER; PHARMACODYNAMICS; PSYCHOPHARMACOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SOMNOLENCE; TREATMENT PLANNING;

ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; HUMANS; MOOD DISORDERS; PSYCHOTIC DISORDERS;

EID: 0038613766     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39065     Document Type: Article

References (92)

1. th Century. Neuropsychobiology 1998; 38: 152-166
2. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982; 170: 717-731
3. Kalinowsky LB, Putnam TJ. Attempts at treatment of schizophrenia and other nonepileptic psychoses with dilantin. Arch Neurol Psychiatry 1943; 49: 414-420
4. Lambert PA, Carraz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel antiépileptique: Le Dépamide. Ann Med Psychol 1966; 1: 707-710
5. Lambert PA, Carraz G, Borselli S, Bouchardy M. Le dipropyl-acetamide dans le traitement de la psychose maniaco-depressive. L'Encephale 1975; 1: 25-31
6. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984; 6: 116-121
7. Vencovsky E, Soucek K, Kabes J. Prophylactic effect of dipropylacetamide in patients with bipolar affective disorders. In: Emrich HM, Okuma T, Müller AA (eds). Anticonvulsants in affective disorders Amsterdam: Excerpta Medica, 1984: 66-67
8. Emrich HM, Dose M, von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorders. In: Emrich HM, Okuma T, Müller AA (eds). Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 45-55
9. Yakezaki II, Hanaoka M. The use of carbamazepine in the control of manic depressive states. J Clin Psychiatry 1971; 13: 173-182
10. Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A, Matsushita T, Naklao T, Ogura C. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. Folia Psychiatr Neurol Jpn 1973; 27: 617-630
11. Okuma T, Inanaga K, Otsuki S, Sarai K. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology 1979; 66: 211-217
12. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782-790
13. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998; 59 (suppl. 5): 51-58
14. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar 1 disorder. Int Clin Psychopharmacol 1999; 14: 277-281
15. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161
16. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455-460
17. Müller-Oerlinghausen B, Grof P, Schou M. Lithium and suicide prevention. Br J Psychiatry 1999; 175: 90-91
18. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomised prospective trial. Pharmacopsychiatry 1996; 29: 103-107
19. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disorders 1985; 8: 243-250
20. McElroy SL, Pop Jr HG, Keck Jr PE et al. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatrie & Psychobiologie 1988; 3: 81-85
21. McElroy SL, Keck Jr PE, Pope Jr HG, Hudson JI. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12: 42S-52S
22. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of schizoaffective disorder - a randomised study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 42-50
23. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983; 44: 236-331
24. Raptis C, Garacia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychiatr Scand 1990; 81 (2): 162-167
25. Garbutt JC, Loosen PT. Is carbamazepine helpful in paroxysmal behavior disorder? Am J Psychiatry 1983; 140: 1363-1364
26. Hakola HPA, Laulumaa VA. Carbamazepine in violent schizophrenia. In: Emrich HM, Okuma T, Müller AA (eds). Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 204-207
27. Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 199-228
28. Monroe RR. Limbic ictus and atypical psychoses. J Nerv Ment Dis 1982; 170: 711-716
29. Litten RZ, Allen JP. Pharmacological therapies of alcohol addiction. In: Miller NS, Gold MS (eds). Pharmacological therapies in drug and alcohol disorders. New York: Marcel Dekker, 1994: 127-141
30. Ritola E, Malinen L. A double blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand 1981; 64: 254-259
31. Dunn RT, Frye MS, Kimbrell TA, Denicoff KD, Leverich GS, Post RM. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacology 1998; 21: 215-235
32. th Century. Neuropsychobiology 1998; 38: 152-166
33. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 (Suppl. 3): S23-S25
34. Eadie MJ, Tyrer JH. Carbamazepine. In: Eadie MJ (eds.). Anticonvulsant therapy - pharmacological basis and practice, 3rd. Ed. Oxford: Churchill Livingstone, 1989: 142-143
35. Krämer G, Bülau P, Blankenhorn V, Stoll KD. Oxcarbazepin und Carbamazepin. Kinetik, Metabolismus, Enzyminduktion und Konsequenzen für den klinischen Einsatz. Münch Med Wschr 1990; 132 (Suppl 1): S71-S74
36. Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinnen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-289
37. Müller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes - Studies in Germany. In: Emrich H, Okuma T, Müller AA (eds.). Anticonvulsants in affective disorders. Amsterdam: Elsevier, 1984: 139-147
38. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990; 3 (Suppl. 1): 21-30
39. Grant SM, Faulds D. Oxcarbazepine - A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-888
40. Emrich HM. Studies with oxcarbazepine (TRILEPTAL) in acute mania. Intern Clin Psychopharmacol 1990; 5 (Suppl. 1): 83-88
41. Emrich HM. Experience with oxcarbazepine in acute mania. In: Modigh K, Robak OH, Vestergaard P (eds.). Whrightson Biomedical Publishing. 1994: 29-36
42. Emrich HM, Altmann H, Dose M, von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders - A preliminary report. Pharmacol Biochem Behav 1983; 19: 369-372
43. Emrich HM, von Zerssen D, Kissling W, Möller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiat Nervenkr 1980; 229: 1-16
44. Lorr M, Klett C, McNair DM, Lasky JJ. Inpatient Multidimensional Psychiatric Scale. Palo Alto/Calif.: Consulting Psychologists Press, 1962
45. Bech-Rafaelson Mania Scale and the Hamilton Depression Scale. Evaluation of homogeneity and inter-observer reliability. Acta Psychiatr Scand 1979; 59: 420-430
46. Velikonja M, Heinrich K. Effect of oxcarbazepine (GP 47.680) on affective and schizoaffective symptoms: A preliminary report. In: Emrich H, Okuma T, Müller AA (eds.). Anticonvulsants in affective disorders. Amsterdam: Elsevier. 1984: 208-210
47. Fähndrich E. Das AMDP-System, Manual zur Dokumentation psychiatrischer Befunde. Berlin: Springer, 1981
48. Beijamini V, Skalisz LL, Joca SR, Andreatini R. The effect of oxcarbazepine of behavioural despair and learned helplessness. Eur J Pharmacol 1998; 347(1): 23-27
49. Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 2000; 10: 223-228
50. Cabrera JF, Mühlbauer HD, Schley J, Stoll KD, Müller-Oerlinghausen B. Long term randomized clinical trial on oxcarbazepine vs. lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry 1986; 19: 282-283
51. Cabrera J, Albrecht J, Müller-Oerlinghausen B. Kombinierte rezidivprophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin. Nervenarzt 1987; 58: 245-249
52. Wildgrube C. Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders. Int Clin Psychopharmacol 1990; 5: 89-94
53. Kouzavkova M, Kostiukova E, Singin A, Mosolov S. Pharmacokinetic prognosis of prophylactic efficacy and side effects of oxcarbazepine in affective and schizoaffective disorders. Eur Neuropsychopharmacol 2000; 10 (Suppl. 2): S94-S95
54. Wittgens W. Oxcarbazepin in der Gerontopsychiatrie. ZNS & Schmerz 2001; 2: 18
55. Macdonald RL, Kelly KM. Antiepileptic drug mechanism of action. Epilepsia 1995; 36 (Suppl 2): S2-12
56. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine in its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74
57. Kristensen O, Klitgaard NA, Jönsson B, Sindrup S. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983; 68: 145-150
58. Theisohn M, Heimann G. Dispositions of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol 1982; 22: 545-551
59. van Heiningen PNM, Eve MD, Oosterhuis B, Jonkman JHG, de Bruin H, Hulsman JA, Richens A, Jensen PK. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-419
60. Anderman F, Schwabe S, McLean MJ, Lloyd P, Baruzzi A. Panel discussion: Part 1. Epilepsia 1994; 35 (Suppl. 3): S20
61. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol 1986; 31: 91-94
62. Dam M, Ekberg R, Loynind Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76
63. Schachter S. The next wave of anticonvulsants - Focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 2000; 14 (3): 229-249
64. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 (Suppl. 5): S37-S46
65. Äikiä M, Kälviäinen R, Sivenius J, Halonen T, Riekkinnen PJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Research 1992; 1: 199-203
66. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529-533
67. Isojarvi JI, Pakarinen AJ, Myllyla VV. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy. Seizure 1997; 6: 207-211
68. Steinhoff BJ, Stoll K-D, Stodieck SRG, Paulus W. Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res 1992; 11: 67-70
69. van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35 (1): 181-188
70. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996; 29: 156-158
71. Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jorgensen T, Overb KF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism. Ther Drug Monit 1993; 15: 11-17
72. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, Di Perri R. Effect of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand 1994; 90: 130-132
73. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995; 28: 26-28
74. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000; 20: 195-203
75. Emrich HM, Dose M, Wolf R. The action of mood-stabilizers in affective disorders: an integrative view as a challenge. Neuropsychobiology 1993; 27: 158-162
76. Aggleton JP, Mishkin M. The amygdala: sensory gateway to the emotions. In: Plutchik R, Kellermann H (eds.). Emotion: Theory, Research and Experience. Orlando: Academic Press, 1986
77. Davis M. The role of the amygdala in fera-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 1992; 13: 35-41
78. Christe W, Krämer G, Vigonius U, Pohlmann H, Steinhoff BJ, Martin JB, Moore A. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Research 1997; 26: 451-460
79. Schachter SC. Oxcarbazepine: current status and clinical applications. Experimental Opinions of Investigative Drugs 1999; 8: 1-10
80. Krämer G. Oxcarbazepin (Trileptal®): Ein neues Antiepileptikum zur Mono- und Kombinationstherapie. Akt Neurologie 2000; 27: 59-71
81. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbamazepine. Epilepsia 1993; 34: 163-165
82. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988; 2: 269-271
83. Pendlebury SC, Moses DK, Eadie MJ. Hyponatremia during oxcarbazepine therapy. Hum Toxicol 1989; 8: 337-344
84. Borusiak P, Korn-Merker E, Holert N, Boenigk HE. Hyponatremia induced by oxcarbazepine in children. Epilepsy Res 1998; 30: 241-246
85. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Pedersen J, Andersen D, Jensen PK. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-227
86. Bill PA, Vigonius U, Pohlmann A, Guerreiro CAM, Kochen S, Saffer D, Moore A. A double-blind, controlled clincial trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Research 1997; 27: 195-204
87. Bülau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34: 311-313
88. Gatzonis SD, Georgaculias N, Singounas E, Jenkins A, Stamboulis E, Siafakas A. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. Neurology 1999; 52: 1918-1919
89. Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149-1152
90. Fattore C, Cipolla G, Gatti G, Limodo GL, Sturm Y, Bernasconi C, Perucca E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787
91. Krämer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia 1991; 32 (Suppl 1): 70
92. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Monza GC. Evaluation of the influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Epilepsia 1991; 32 (Suppl. 1): 71